Loading
A Shanghai cancer genomics company whose OriMIRACLE S blood test tracks a tumour's shared mutations to look for leftover cancer.
OrigiMed is a Shanghai genomics company. Its employees co-authored the development of OriMIRACLE S, a tumour-informed residual disease test using clonal variants chosen by its OriSelector algorithm (Cancer Medicine 2023), and the whole-exome sequencing behind a 2024 osteosarcoma ctDNA study at Sun Yat-sen University (eClinicalMedicine 2024).
OrigiMed's personalised blood test for leftover cancer, which deliberately tracks only mutations shared by every tumour cell.
Residual disease blood tests extend to bone sarcoma. The methods state a variant allele frequency limit of 0.01 per cent.
A residual disease test built on clonal variants only, which detects the trunk of the tumour and by design not its branches.
Shares Tumor-informed deep sequencing of ctDNA detects minimal residual disease and predicts relapse in osteosarcoma, Monitoring of gastrointestinal carcinoma via molecular residual disease with circulating tumor DNA using a tumor-informed assay, OriMIRACLE S, MRD / molecular residual disease testing.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/